Servier Ranked Among Top Companies Across Several Categories in 2024 PatientView Corporate Reputation of Pharma Survey

News provided by

May 28, 2025, 16:35 ET

Servier U.S. ranked #1 across several categories

U.S. recognition follows last month's announcement that Servier made the top ten list of organizations evaluated by PatientView globally

BOSTON, May 28, 2025 /PRNewswire/ -- Servier today announced that the company was ranked among the top companies across several categories in PatientView's 2024 Corporate Reputation of Pharma in the U.S. survey. This annual survey captures insights from more than 350 patient organizations reflecting their firsthand experiences, perceptions and familiarity with pharmaceutical companies.

This ranking comes on the heels of PatientView's Global Reputation of Pharma Survey – where Servier earned a spot in the Top 10 of pharmaceutical company reputations among patient organizations. This marked the first time in the Top 10 globally, reinforcing our ever-increasing commitment to patients and the organizations that represent them.

"Being recognized at the top of PatientView's annual rankings is not just an honor, it's a meaningful reflection of our continued commitment to listening to patients, collaborating closely with patient advocates, and delivering solutions that truly meet needs," said Nicolas Garnier, Chief Patient Officer, Servier. "This recognition is a reflection of our deep, ongoing commitment to putting patients first and acknowledging the essential role they play in shaping our work at every stage. This kind of external validation reinforces that we are listening, learning, and taking the right actions to truly support patients and the communities that represent them."

U.S. patient organizations also ranked Servier in the top two across all categories and first in several categories: Transparency on Data, Integrity, Beyond the Pill, Engagement in R&D.

Globally, Servier was also ranked among the top 10 companies - underscoring the company's growing reputation and meaningful impact on patients worldwide.

"At Servier, engaging meaningfully with patient organizations and ensuring access to medicines are fundamental priorities," said Wendy Poage, Vice President of the Patient Office at Servier. "We're honored to be recognized in the Patient View report for our integrity and commitment to delivering support that goes beyond the pill. This kind of external validation reinforces that we are listening, learning, and taking the right actions to truly support patients and the communities that represent them."

For more information on Servier Pharmaceuticals patient support services, please visit servier.us/patient-support and https://www.servierone.com/.

About the Corporate Reputation of Pharma Survey

2024 'Corporate Reputation of Pharma' survey of patient groups worldwide was conducted December 2024 to March 2025 and answered by 372 US patient groups, representing over 13 million US patients during the past year. The PatientView annual Corporate Reputation of Pharma survey gives patient-advocacy groups an opportunity to comment on, and assess, the pharma industry's performance. Companies are ranked against their peers. The survey results reinforce the dedication, commitment and hard work companies invest internally to ensure engagement with patients and advocacy groups is reflective of the patients they serve.

About Servier

Servier is a global pharmaceutical group governed by a nonprofit foundation, committed to making a meaningful social impact for patients and contributing to a sustainable world.

Its unique governance model ensures its independence, while supporting long-term innovation, with 100% of its profits reinvested in the Group's development.

As a world leader in hypertension and venous diseases and major player in cardiometabolism, Servier drives transformative innovation to support patients with chronic conditions and improve their day-to-day lives through a holistic approach, which includes making patient adherence and control a priority across the globe. Its ambition is to become a leading player in rare cancers, which is why the Group invests heavily in oncology, allocating close to 70% of its R&D budget to this field. By leveraging precision medicine, Servier develops therapies that are more targeted and more effective.

Bolstered by its success in oncology, Servier has expanded into neurology, a key driver of future growth. The Group is focused on a select number of neurodegenerative diseases, where accurate patient profiling enables targeted therapeutic responses through precision medicine.

To open up wider access to high-quality, affordable care, Servier also offers an extensive range of generic medicines, building on well-established brands in France, Eastern Europe, and Brazil. In all its activities, and at every stage of the medicine life cycle, the Group integrates the patient's voice.

Headquartered in France, Servier operates in around 140 countries. In 2023-2024, the Group, which employs over 22,000 people worldwide, achieved revenues of €5.9 billion.

More information on our website : servier.com

Media Contact:

Sara Noonan

[email protected]

SOURCE Servier Pharmaceuticals